The relationship between the skeletal and immune systems has been extensively explored in the past decade. As excessive inflammation and pathologic bone destruction are often coupled, establishing the scientific basis of an osteo-innate-immunological system is an important issue in the field of bone biology. Gene targeting technology is a powerful tool that may allow the identification of factors that regulate both the innate immune system and bone metabolism. Recently, we identified several new molecules that are critical osteo-innate-immunological regulators both in vivo and in vitro by using knockout mice. These findings have important implications for the field of skeletal biology, and might help the development of a new era of highly efficient molecular-based medicines for bone destructive diseases.
Introduction
Gene function studies using knockout mouse technology have provided an invaluable opportunity in the research field of skeletal biology. Bone resorbing osteoclasts are derived from the myeloid lineage, thus many mutant mice harboring skeletal phenotypes due to disregulated osteoclastogenesis also show immunological abnormalities [1] . The coupling of aberrant inflammation and enhanced bone destruction in murine gene knockout models can be investigated via the screening of such osteo-innate-immunological phenotypes, to hopefully provide novel therapeutic targets that can be used to treat skeletal diseases. We have applied this technology to identify several new molecules that are pivotal in the regulation of the osteo-innate-immunological system. Here we summarize the skeletal and innate-immunological phenotype of Jdp2, RANKL, OPG, Sbno2, TANK and AZI2-deficient mice [2] [3] [4] [5] [6] , and introduce the molecular mechanisms of these genes.
Regulation of osteoclast and neutrophil differentiation by Jdp2
Jdp2 is a basic leucine zipper family transcription factor involved in various cellular functions such as apoptosis and differentiation [7, 8] . Transcription factor Activating protein 1 (AP-1) is composed of Jun family, Fos family, and ATF family proteins. It has been established that Jdp2 binds to Jun and ATF family proteins, leading to the suppression of the transcriptional activity of AP-1 components [8] . Recently, it was reported that Jdp2 inhibited histone acetyltransferase activity that regulates the epigenetic status [9] . Furthermore, knockdown of Jdp2 inhibited in vitro osteoclastogenesis [10] . Despite the importance of transcriptional repression and implications for in vitro osteoclastogenesis, the role of Jdp2 in vivo and its pleiotropic functions are largely unknown. To elucidate the physiological functions of Jdp2, we generated Jdp2-deficient mice. These mice exhibited severe osteopetrosis caused by impaired osteoclastogenesis. In vitro REVIEW RANKL-induced osteoclastogenesis was completely abolished in Jdp2-deficient cells, and this phenotype was rescued by the retroviral expression of Jdp2. Importantly, Jdp2 induced by RANKL stimulation is c-Fos dependent, indicating that the c-Fos-Jdp2 signaling is important for osteoclastogenesis [2] . Jdp2 is also highly expressed in neutrophils. Surprisingly, Jdp2-deficient neutrophils exhibited an impaired expression of Ly6G, which is a differentiation marker of neutrophils. Furthermore, Jdp2-deficient neutrophils exhibited significantly impaired apoptosis and bactericidal activity. It has been reported that an extracellular chromatin structure, termed neutrophil extracellular trap (NET), is secreted from stimulated neutrophils and can bind and kill bacteria. Importantly, NET formation in Jdp2-deficient neutrophils was dramatically impaired. With regard to impaired neutrophil differentiation and function, Jdp2-deficient mice are highly susceptible to bacterial and fungal infection [2] . The expression levels of anti-apoptotic genes such as Bcl-2 and primary granule genes such as MPO and Cathepsin G were dramatically enhanced in neutrophils, and all these genes are C/EBPα target genes. Immunoprecipitation and luciferase reporter assays revealed that Jdp2 directly binds to C/EBPα, inhibiting its transcriptional activity. Because Jdp2 inhibits histone acetyltransferase activity, we performed chip-seq analysis using an acetyl histone antibody and discovered that the ATF3 promoter region was highly acetylated by Jdp2 deficiency. Expression level of ATF3 was enhanced in Jdp2-deficient neutrophils, and retroviral overexpression of ATF3 in wild-type neutrophils inhibited Ly6G expression [2] . Collectively, these findings suggest that Jdp2 is a pivotal "osteo-innate-immunological" regulator, and that Jdp2 suppression might provide the basis for a novel therapeutic strategy to treat inflammatory bone destruction (Fig.1 ).
RANKL-OPG axis regulates bone metabolism and pro-inflammatory cytokine production
The generation of bone resorbing osteoclasts is tightly regulated by two proteins, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG) [1] . Mice deficient in RANKL exhibit severe osteopetrosis due to the complete absence of bone degrading osteoclasts [11] . In contrast, OPG-deficient mice present with a severe osteoporotic phenotype due to increased osteoclastogenesis [12, 13] . RANKL is a type II transmembrane protein expressed in bone-forming osteoblasts, which is cleaved by matrix metalloproteases to release soluble-form RANKL into the serum. The binding of RANKL to its receptor RANK on macrophages induces the expression of both osteoclast-specific genes and osteoclastogenesis. In contrast to RANKL, OPG is a soluble protein secreted from osteoblasts that blocks the RANKL-RANK binding. Thus, the RANKL-OPG balance is critical for proper osteoclastogenesis [1] . Despite the obvious importance of the RANKL-OPG axis in bone metabolism, function of this signaling axis in innate immunity remains unclear. Following bacterial infection or administration of the endotoxin lipopolysaccharide (LPS), serum RANKL levels decrease while OPG levels increase [3] . When we treated macrophages first with RANKL for 24 h and then with LPS, pro-inflammatory cytokine production was significantly impaired. To evaluate innate-immunological function of RANKL-OPG signaling axis, we injected LPS into RANKL and OPG-deficient mice and quantified the serum cytokine levels. Pro-inflammatory cytokine production was shown to be significantly elevated in RANKL-deficient mice, but impaired in the OPG-deficient model. Furthermore, RANKL-deficient mice were susceptible to LPS-induced death, while RANKL injection prior to the administration of LPS was protective against LPS-induced death [3] . Thus, these findings suggest that the RANKL-OPG axis plays critical roles both in skeletal system and in controlling septic shock.
Regulation of osteoclast fusion by the transcriptional repressor, Sbno2
Inflammatory cytokines are produced by the activation of NF-êB [14] . Anti-inflammatory cytokines such as IL-10 are also targets of NF-êB. When IL-10 binds to its receptor IL-10R, the transcription factor STAT3 is activated and anti-inflammatory responses are induced [15] . Expression of DExD/H helicase family corepressor, Sbno2 is induced by IL10 in a STAT3-dependent manner. Previous in vitro study revealed that Sbno2 negatively regulated NF-êB activation, suggesting that the IL-10-STAT3-Sbno2 axis is critical for anti-inflammatory responses [16] . Despite the importance of NF-êB regulation, the physiological role of Sbno2 is completely uncharacterized [4] . Recently, our group generated Sbno2-deficient mice and revealed they exhibited normal proinflammatory cytokine production and NF-êB activation in response to TLR ligands. Furthermore, Sbno2 deficient mice exhibited normal susceptibility to Staphylococcus aureus infection. Thus, Sbno2 is dispensable for the negative regulation of inflammation. Unexpectedly, Sbno2 is induced by RANKL by Jdp2 dependent manner, and Sbno2-deficient mice exhibited a severe osteopetrosis caused by impaired osteoclast multinucleation. In vitro RANKL-induced osteoclastogenesis was impaired, but expression levels of osteoclast differentiation markers such as TRAP and cathepsin K were normal, suggesting that osteoclast fusion was defective in Sbno2-deficient mice [4] . Importantly, the expression levels of DC-STAMP, a critical gene of osteoclast fusion [17] , were significantly reduced, and retroviral overexpression of DC-STAMP rescued the fusion defect in Sbno2-deficient osteoclasts. Despite the decreased osteoclast fusion, the bone formation rate in Sbno2-deficient mice was decreased. Intriguingly, the expression of Jagged 1 in Sbno2-deficient osteoblasts was significantly impaired and recombinant Jagged 1 stimulation rescued the impaired osteoblastogenesis. To gain insights into the molecular mechanism of Sbno2 in osteoclasts, we performed chip assay of DC-STAMP promoter, and discovered that the binding of Tal1, a transcriptional repressor [18] , was highly enriched in the DC-STAMP promoter of Sbno2-deficient osteoclasts. Moreover, immunoprecipitation assays revealed that Sbno2 directly binds to Tal1 and inhibits its DC-STAMP repressive activity [4] , leading to enhance the access of MITF, a positive regulator of DC-STAMP expression to DC-STAMP promoter. Thus, these findings suggest that Sbno2 regulates osteoclast fusion by suppressing Tal1 activity, and the osteoclast specific inhibition of Sbno2 might be a promising strategy to treat osteoporosis (Fig. 2) . 
Negative regulation of osteoclast formation by TLR/IFN signaling adaptor proteins such as TANK and AZI2
TNF receptor-associated factor 6 (TRAF6) plays a pivotal role in TLR/IL-1R superfamily signaling [14] . The main feature of the TLR/IL-1R superfamily is its intracellular domain, named the Toll/IL-1 Receptor (TIR) domain. When IL-1R or TLR are stimulated by IL-1 or bacterial components, respectively, the TIR-domain-containing adaptor protein, MyD88, is activated, which is followed by recruitment of IRAKs. After the activation of IRAKs, they in turn dissociate from the receptor complex and bind to TRAF6 to activate downstream signaling [14] . In a similar manner to both IL-1R and TLR signaling, RANK signaling can also activate TRAF6, recruiting it to the intracellular region of RANK and ultimately leading to the ubiquitination of TRAF6 [19] . Recently, we reported that the TRAF family member-associated NF-kB activator (TANK) suppresses TLR and B-cell receptor (BCR) signaling by suppressing the TRAF6 ubiquitination [20] . Intriguingly, RANKL stimulation potently induced TANK expression in osteoclasts, thus inhibiting the ubiquitination of TRAF6 and allowing osteoclast differentiation [5] . Expression of TANK was also enhanced during osteoblastogenesis, while TANK deficiency gave rise to increased bone formation as a result of enhanced IL-11 production. As expected, TANK-deficient mice exhibited enhanced bone mineral density, but decreased trabecular bone volume due to enhanced bone formation and osteoclastogenesis [5] . Thus, these discoveries suggest that TANK is a negative feedback regulator of osteoclastogenesis and bone formation (Fig. 3) .
Other than RANKL, osteoclastogenesis is also regulated by interferons (IFNs). For instance, type-I interferons such as IFN-â are induced by RANKL and play as a negative feedback regulator of osteoclastogenesis [21] . Viral infection is recognized by the immune system via the RIG-I-like receptor family genes, which activate TNFR-associated factor family member-associated NF-êB activator binding kinase 1 (TBK1) and IFN regulatory factor 3 (IRF3) to induce type-I interferons [14] . Recent reports suggest that the activation of TBK-1 is modulated by binding partner proteins, such as TANK, 5-azacytidine-induced protein 2 (AZI2) and TBK1 binding protein 1 (TBKBP1), which have all been shown to interact with TBK1 to regulate interferon production [14] . Contrary to previous reports, our TANK-deficient mice exhibited normal IFN-â production, but increased osteoclastogenesis [22] . Furthermore, AZI2-and TBKBP1-deficient mice-derived macrophages exhibited normal IFN-â production [22] . Unexpectedly, AZI2-deficient mice, but not TBKBP1-deficient mice, presented with a severe osteoporotic phenotype due to increased osteoclast longevity [6] . During osteoclastogenesis the expression of AZI2 is significantly down-regulated, conditions that are emulated in the AZI2-deficient model. AZI2-deficient osteoclasts have been shown to exhibit enhanced phosphorylation of c-Src, which is involved in osteoclast survival, yet their longevity is not affected by suppression of Hsp90, an inhibitory molecule of c-Src activation. Strikingly, administration of a c-Src inhibitor rescued the osteoporotic phenotype of AZI2-deficient mice. Recent report suggested that Cdc37 is a binding partner of Hsp90 and we discovered that AZI2 directly binds to Cdc37, leading to the proper inhibition of c-Src activation [6] . Thus, these findings indicate that the AZI2-Cdc37-Hsp90 complex is critical for fine-tuning osteoclast survival (Fig. 4) .
Concluding remarks
The administration of monoclonal antibodies directed against RANKL is highly effective in the treatment of osteoporosis [23] . However, recent reports suggest that some adverse effects such as infection, hypocalcemia, and osteonecrosis of the jaw may be observed with such treatments [23, 24] . Bisphosphonate, which is a potent inhibitor of osteoclastogenesis, is widely used as a therapeutic agent for osteoporosis. However, there is little benefit associated with long-term continued bisphosphonate therapy for the prevention of osteoporotic fracture [25] . Furthermore, recent advances in cytokine-targeted monoclonal antibody therapies have shown great innovation in the treatment of rheumatoid arthritis [26, 27] , yet only limited numbers of patients are ever able to enter drug-free remission. Thus, the emerging molecules of interest at the interface between innate immune system and bone metabolism introduced here may offer new, alternative suggestions in the pursuit of a more sophisticated strategy to regulate bone-destructive diseases. 
